Compare Neurocrine Biosciences Inc (NBIX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Xylem, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | XYL | |
|---|---|---|
Market Cap | $17.40B | $28.67B |
Sector | Health | Industrials |
52-Week High | $180.55 | $152.95 |
52-Week Low | $123.10 | $106.34 |
Enterprise Value | $16.49B | $29.92B |
Dividend Yield | — | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
